Feature articles
We are what we eat: Jim Mellon exclusive
Phil Newman - 0
Longevity, biotech, investment, sustainability and ethics: Jim Mellon's new book, MOO'S LAW, addresses the opportunities and challenges of our need for protein.
Getting time with...
2021 hits the longevity ground running
Highlights from longevity research, trials and funding in January 2021
Hundreds of companies are working to develop treatments to slow down aging and increase healthy...
Juvenescence (1): from strength to strength in R&D and investment firepower
Juvenescence's Greg Bailey on transformative scientific opportunities, immuno-resilience, modifying aging and funding.Continuing our series of interviews with our Advisory Panel members, we spoke to Greg...
Latest news
New Buck Institute study is treasure trove for longevity research
Compound that extends lifespan in worms also slows bone loss in mice.
Scientists at the Buck Institute for Research on Aging conducted a longitudinal and functional study...
Juvenescence (1): from strength to strength in R&D and investment firepower
Juvenescence's Greg Bailey on transformative scientific opportunities, immuno-resilience, modifying aging and funding.Continuing our series of interviews with our Advisory Panel members, we spoke to Greg...
Let’s initiate trials of potential geroprotective therapies
Dr Lynne Cox explains the importance of geroprotectors – especially during COVID-19.
This month The Lancet launches its own journal on Longevity, publishing clinically-focused Longevity and...
COVID-19: Leading clinician calls for focus on the biology of aging
Dr Nir Barzilai predicts that rapamycin could decrease severity of coronavirus in the elderly by 50%.
Longevity.Technology: When it comes to the world of Longevity...
Tina Woods: Prevention is vital for Longevity
Longevity International’s Tina Woods tells us how the Longevity industry is releasing us from being trapped in the cycle of ill health and chronic...
Longevity FinTech: a new contract between finance and aging
Academic proposes that FinTech and InsurTech can be a key enabler of new financial approaches for older people.
Ira Sobel is the founder of FinTech...
Why government must unlock biotech’s potential to maximise Longevity
Breanna Deutsch joins us for a guest editorial to advocate for the increased prioritisation of government funding for Longevity in the US.
Breanna Deutsch has...
Longevity big-hitters join our current investment round
Phil Newman - 0
Some news of our own: Key investors join the First Longevity funding round.
Among those participating in this second stage funding for First Longevity are...
Journalism Matters Week: We’re doing our bit!
Phil Newman - 0
2020 has been an incredible year. For journalists, and a huge number of other professions, it has been one of the biggest periods of...
Proposed budget cut: reduced Longevity for EU citizens?
European Longevity Initiative writes an open letter addressing concerns that the European Research Council's budget has been cut.
Suggested changes to the proposed ERC budget...
The metformin debate swings both ways
Research on metformin is not at the beginning of the end, but it is, perhaps, at the end of the beginning.
The drug giveth and...
Latest news
Shining a Sheekey light on science
Introducing Eleanor Sheekey and The Sheekey Science Show – taking science communication to a whole new level.The Sheekey Science Show looks at all sorts of science...
We are what we eat: Jim Mellon exclusive
Phil Newman - 0
Longevity, biotech, investment, sustainability and ethics: Jim Mellon's new book, MOO'S LAW, addresses the opportunities and challenges of our need for protein.
Getting time with...
2021 hits the longevity ground running
Highlights from longevity research, trials and funding in January 2021
Hundreds of companies are working to develop treatments to slow down aging and increase healthy...
You might also like
Exclusive video interview with Erin Sharoni of JUVICELL
Phil Newman - 0
We talk fasting, lifespan and longevity supplements with JUVICELL's co-founder, Erin Sharoni.
Recently, we were excited to cover the launch of brand-new longevity supplement JUVICELL,...
Longevity supplement innovator soft-closes $5.5m
Ponce de Leon: the longevity supplement company behind Rejuvant could raise up to $15m in current series B round.
Ponce de Leon Health, a company...
Swiss longevity company builder launches
Swiss-based Maximon already moving forward with companies focused on precision supplements and personalised longevity advice.
Already touted as a hotbed of longevity innovation, Switzerland is...
New aging clock is a key longevity tool
A new aging clock that's close to the theoretical limit of accuracy boasts unprecedented precision and offers new insights into how the aging process...
Longeveron completes longevity clinical trial
Longeveron announces successful completion of phase 2b clinical study of Lomecel-B infusion to treat aging frailty.
Longeveron Inc, a clinical stage biotechnology company developing cellular...
